Precision Blood Testing Now

Detecting cancer can be challenging due to limited existing screening tests, long turnaround times, high costs, and invasive procedures. OncoSure's innovative technology allows for early detection and provides crucial information for guiding further imaging tests with our detailed Oncosome count.

OncoSure's advanced cancer screening technology utilizes rapid in situ hybridization and DNA fluorescent probes, offering comprehensive cancer screening with high accuracy. Our approach includes a rapid SITU Hybridization Platform, DNA Fluorescent Probes for ploidy detection, and inexpensive density gradient and low sequential centrifugation, which enable comprehensive screening for aneuploidy of all chromosomes. 

Oncosomes:
Oncosomes are microscopic, cancer-associated extracellular vesicles. By isolating and analyzing these, OncoSure achieves high specificity and sensitivity in early cancer detection.

Advanced Hybridization Technology
Utilizing rapid in situ hybridization and DNA fluorescent probes, OncoSure offers comprehensive screening for aneuploidy across all chromosomes, ensuring thorough and accurate results.

Expert Leadership: Dr. Ramesh Babu
Developed under the guidance of Dr. Ramesh Babu, a pioneer in cancer research with extensive experience in oncology and molecular diagnostics, OncoSure reflects a commitment to advancing early detection methods for improved patient outcomes.

 Empower your patients with non-invasive, whole-body early detection. Designed for clinical workflows. Trusted by physicians. Powered by science.  

We know that waiting for test results can be stressful, so we make sure to provide fast turnaround times for all of our tests.

We believe that everyone should have access to high-quality blood testing services, which is why we offer affordable pricing options.

We pride ourselves on providing exceptional customer service and support to all of our clients, from start to finish.